Tempus CEO Reveals Competing Bid, Merck/Moderna RFP Win, and $330M+ ADLT Pricing Upside
TEM sits 68% above its 52-week low of $40.77.
Summary
Tempus CEO Eric Lefkofsky disclosed new details about the Personalis acquisition, including a competing bid that accelerated the deal, a Merck/Moderna RFP win, and $330M+ in ADLT pricing upside.
Key Events · M&A and Partnerships · TEM
-
Competing Bid Accelerated Acquisition
Lefkofsky revealed a competing bidder emerged during the sale process, with bids only $0.75 apart ($17.00 vs Tempus' $16.25), accelerating Tempus' acquisition timeline by a few months.
-
Merck/Moderna RFP Win
Tempus won the Merck/Moderna V940 melanoma vaccine sequencing RFP, making Tempus the national rollout partner for the FDA-approved product, with sequencing as a component of the manufacturing process.
-
ADLT Pricing Upside
Tumor-only ADLT pricing effective January 1 adds $80-100M in revenue/margin benefit; liquid biopsy ADLT pricing in H2 2027 adds $250-300M.
-
Personalis Trading Above Deal Price
Lefkofsky dismissed Personalis trading above the $16.25 deal price as 'no sense,' citing Tempus, Merck, and ARK collectively controlling 35-40% of the vote and no topping bid expected.
Analysis · TEM · Industrial Applications And Services
This Morgan Stanley conference transcript contains several material new disclosures about the Personalis acquisition and Tempus' broader business. Lefkofsky reveals a competing bidder emerged during the sale process, with bids only $0.75 apart, which accelerated Tempus' acquisition timeline. He also discloses Tempus won the Merck/Moderna V940 melanoma vaccine sequencing RFP, positioning Tempus as the national rollout partner for a potentially blockbuster drug. The CEO provides new financial guidance: tumor-only ADLT pricing effective January 1 adds $80-100M in revenue, while liquid biopsy ADLT pricing in H2 2027 adds $250-300M. He also addresses the unusual situation of Personalis trading above the $16.25 deal price, dismissing the premium as irrational given Tempus, Merck, and ARK collectively control 35-40% of the vote. The disclosure of a $46.00 floor price on Tempus stock that would give Personalis a termination right is a new risk factor not previously highlighted.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 35.7% of the 1179 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.44%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TEM was trading at $68.60 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $12.4B. The 52-week trading range was $40.77 to $104.32. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.